) --Welcome to TheStreet's live-blog coverage of the

American Society of Clinical Oncology

(ASCO) annual meeting. It's Saturday, the first full day of data presentations at the largest annual gathering of cancer drug researchers in the world.

On the schedule for today: This morning,

Johnson & Johnson

(JNJ) - Get Report

will be presenting results from the phase III study of Zytiga in "pre-chemo" prostate cancer patients. These data have significant commercial implications not only for J&J but also






. Investors have been waiting for months to get their hands on these Zytiga data.

In the afternoon,

Aveo Pharmaceuticals

(AVEO) - Get Report

will present final data from a phase III study that compared its kidney cancer drug tivozanib to

Onyx Pharmaceuticals'


Nexavar. An important poster on Onyx's multiple myeloma drug carfilzomib also goes up today.

Other noteworthy stocks on the ASCO data docket Saturday include


(EXEL) - Get Report



(ARQL) - Get Report





Follow this live blog throughout the day for continuous updates and reports from the ASCO meeting. I'll be reporting on clinical data presentations as I see and hear them, and I'll be blogging from the hallways, exhibition hall and meeting rooms, giving you a real-time perspective on the investor-worthy buzz.

The blog will also capture tweets from a select and experienced group of analysts, doctors and journalists -- all of whom will add their perspective and insight into the ASCO meeting.

I welcome your comments and questions on this live blog, too, which I'll do my best to answer and publish as time permits.

--Written by Adam Feuerstein in Chicago.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:






and become a fan on


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.